Corporate Philosophy

Positioning of Mid-Term Management Plan 2028 and Growth Strategy

The Mid-Term Management Plan 2028 serves as the first phase of the roadmap toward realizing ASKA VISION 2035. Based on a strategy consisting of two foundations and five strategic pillars, the plan aims to achieve both the steady growth of existing businesses and the establishment of future growth platforms, thereby building a sustainable earnings base.
By the final year of the plan, fiscal 2028, ASKA Pharmaceutical Holdings aims to achieve net sales of ¥85.0 billion. At the same time, the Company will further strengthen its business foundation with a view toward the early achievement of ¥100.0 billion in net sales, supporting long-term sustainable growth.

Our Purpose

We will realize a healthy tomorrow and future for all lives

Mid-Term Management Plan 2028

Slogan

Deepening Our Core Strengths and Building the Business Foundation to Support Global Expansion for Sustainable Growth

FY2028 Financial Targets

Net Sales

¥85.0billion

Operating Profit Margin

10%

ROE

10%

Total payout ratio

40%

The Five Pillars Driving Growth

Domestic Pharmaceutical

Strengthening Profitability through Further Expansion in Specialty Areas

Drug Discovery

Accelerating Global Expansion

Global

Strengthening Business Foundations through New Plant Operations

Animal Health

Expanding Business through New Product Launches and Overseas Expansion

Testing and Around-the-Pill

Expanding the Testing Business through Trace Analysis Technologies and Broadening into Adjacent Healthcare Fields

Two Strategic Foundations

Financial Strategy

Advanced management with a focus on the cost of capital

Strengthening the Management Foundation

Strengthening the management infrastructure to execute strategies

6 Material Issues

1

Promotion of environmental management

2

Developing diverse human resources to enhance corporatevalue

3

Contributing to women'shealth and animal health

4

Stable supply of high-quality products and provision of appropriate information

5

Respect for human rights

6

Strengthening governance

ASKA Pharmaceutical Holdings' VISION 2035

To achieve sustainable growth and continue contributing to society over the next decade and beyond, ASKA Pharmaceutical Holdings has established its “Vision for 2035.” Through purpose-driven business management and execution, we will realize our Vision for 2035 and continue creating value for all stakeholders.

Our Purpose

We will realize a healthy tomorrow and future for all lives

 

Long-Term Vision ASKA VISION 2035

Mid-Term Management Plan

Corporate Message

For a Healthy Tomorrow and Future.

We will use our accumulated expertise and knowledge in specialty areas to build a society where women can shine even more brightly, and to improve animal welfare. Based on our business as a specialty pharma company, we will promote environmental, social and governance (ESG) initiatives, and take on the challenge of helping to realize a prosperous society, while the animal health business and testing business exercise synergies.

Logo Concept

Aspirations behind the Corporate Symbol About the Design Elements

A development-oriented corporate culture that continuously releases new drugs
→enterprising spirit that continues to develop and grow.
Strong corporate strength rooted in social contribution
→A: Active / S: Service / K(A): Kind to human life

The two ampules represent a bird in flight: "a sense of flight," "forward-looking," and "soaring growth."